Haploinsufficiency, rather than the effect of an excessive production of soluble CD95 (CD95{Delta}TM), is the basis for ALPS Ia in a family with duplicated 3' splice site AG in CD95 intron 5 on one allele.
暂无分享,去创建一个
J. Valcárcel | M. Gahr | M. Lenardo | A. Rösen‐Wolff | J. Roesler | M. Ryser | Lixin Zheng | José-María Izquierdo
[1] F. Rieux-Laucat,et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. , 2004, The New England journal of medicine.
[2] F. Uckun,et al. CD95 (APO‐1/FAS) deficiency in infant acute lymphoblastic leukemia: detection of novel soluble Fas splice variants , 2003, European journal of haematology.
[3] T. Dull,et al. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease. , 2002, Blood.
[4] Thierry Lamy,et al. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. , 2002, Blood.
[5] P. Huie,et al. Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. , 2002, Blood.
[6] J. Puck,et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. , 2001, Blood.
[7] A. Marx,et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. , 2001, Blood.
[8] J. Valcárcel,et al. The apoptosis-promoting factor TIA-1 is a regulator of alternative pre-mRNA splicing. , 2000, Molecular cell.
[9] J K Frederiksen,et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. , 2000, Science.
[10] U. Dianzani,et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. , 2000, Blood.
[11] M. Tomonaga,et al. Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO‐1) in adult T‐cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis , 1999, British journal of haematology.
[12] Shigeki Tanaka,et al. mRNA expression of variant fas molecules in acute leukemia cells , 1999, American journal of hematology.
[13] J. Puck,et al. Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II , 1999, Cell.
[14] S. Baekkeskov,et al. A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. , 1999, Transplantation.
[15] M. Gahr,et al. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. , 1999, Experimental hematology.
[16] M. Peter,et al. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Puck,et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. , 1999, American journal of human genetics.
[18] P. Krammer,et al. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. , 1999, The Journal of clinical investigation.
[19] Jane Y. Wu,et al. Alternative splicing and programmed cell death. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[20] J. Puck,et al. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. , 1998, The Journal of pediatrics.
[21] Y. Rao,et al. Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[22] S. Holland,et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[23] E. Jaffe,et al. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. , 1997, Blood.
[24] S. Nagata,et al. Apoptosis by Death Factor , 1997, Cell.
[25] L. Notarangelo,et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. , 1997, Blood.
[26] K. Sullivan,et al. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. , 1996, The New England journal of medicine.
[27] F. Rieux-Laucat,et al. Clinical, immunological, and pathological consequences of Fas-deficient conditions , 1996, The Lancet.
[28] P. Schur,et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. , 1996, The Journal of clinical investigation.
[29] H. Horvitz,et al. An Alternatively Spliced C. elegans ced-4 RNA Encodes a Novel Cell Death Inhibitor , 1996, Cell.
[30] G. Starace,et al. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. , 1996, Journal of immunology.
[31] J. Mountz,et al. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. , 1995, The Biochemical journal.
[32] Warren Strober,et al. Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.
[33] F. Rieux-Laucat,et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. , 1995, Science.
[34] A. Strasser,et al. Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. , 1995, Current opinion in immunology.
[35] G. Fiucci,et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. , 1995, Journal of immunology.
[36] E. Alnemri,et al. Cloning and Expression of Four Novel Isoforms of Human Interleukin-1β Converting Enzyme with Different Apoptotic Activities (*) , 1995, The Journal of Biological Chemistry.
[37] L. Wang,et al. Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death , 1994, Cell.
[38] Matthew J. Brauer,et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.
[39] C. Thompson,et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.
[40] E. Jaffe,et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. , 1992, The Journal of clinical investigation.
[41] Virginia C. Canale,et al. Chronic lymphadenopathy simulating malignant lymphoma. , 1966, The Journal of pediatrics.
[42] J. Mountz,et al. Regulation of apoptosis in immune cells , 2005, Journal of Clinical Immunology.
[43] G Ruberti,et al. Soluble Fas/Apo-1 splicing variants and apoptosis. , 1996, Frontiers in bioscience : a journal and virtual library.
[44] J. Russell,et al. Activation-induced death of mature T cells in the regulation of immune responses. , 1995, Current opinion in immunology.